EPCAM and neoplasm: A novel human IgG1 anti-EpCAM antibody, adecatumumab (MT201), exhibited dose-dependent anti-tumor activities and hightolerance for metastatic breast cancer (MBC), primarily through effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [7].